Download
Title Page & Editorial Board

back to 2013, vol. 19, b. 3
Journal of IMAB - Annual Proceeding (Scientific Papers)
Publisher: Peytchinski, Gospodin Iliev
ISSN: 1312 773X (Online)
Issue: 2013, vol. 19, book 3;
Subject Collection: Medicine
Page: 442-447
DOI: 10.5272/jimab.2013193.442
Published online: 04 August 2013

J of IMAB. 2013 Jul-Dec;19(3):442-447;
THE CYTOKINE IP-10 IN CHRONIC HBV AND HCV INFECTION
Nina S. Nikolova Corresponding Autor, Krasimir Antonov, Deian Jelev, Lyudmila Mateva, Zahariy Krastev.
Clinic of Gastroenterology, University Hospital "St. Ivan Rilski" - Sofia,
Medical University - Sofia, Bulgaria.


ABSTRACT:
Introduction: IP-10 it has been studied as a predictor of treatment response in chronic HCV infected patients. The data for the HBV infection are not enough.
Aim: To compare IP-10 levels in patients with chronic HBV /CHB/ and HCV infection /CHC/ and their relation to liver disease and treatment response.
Material and methods: 20 patients - with CHC genotype 1 infection /on standard bi-therapy/ and 32 patients with CHB /21 pts - NUC; 11 pts - IFN/.
Results: The IP-10 did not correlate with sex, age, ALT and liver fibrosis. The basal IP-10 were lower in patients with CHB (p=0,017). There was a difference in IP-10 baseline levels among the HCV patients with or without RVR (p=0,007). A negative correlation was found between basal IP-10 and RVR (r= -0,508; p=0,008).
Conclusion: IP-10 could predict virological response in patients with CHC on standard bi-therapy, but not in HBV infected patients on standard therapy.

Key words: IP-10, chronic HCV, HBV infection, response.

- Download FULL TEXT /PDF 849 KB/
Please cite this article as:
Nikolova NS, Antonov K, Jelev D, Mateva L, Krastev Z. THE CYTOKINE IP-10 IN CHRONIC HBV AND HCV INFECTION. J of IMAB. 2013 Jul-Dec;19(3):442-447. DOI: 10.5272/jimab.2013193.442.

Correspondence to: Nina S. Nikolova, MD, Sector "General Medicine", University Hospital "St Ivan Rilski" – Clinic of Gastroenterology - Sofia, Medical University - Sofia, Bulgaria; 15, Acad. Ivan Geshov, bld., 1431 Sofia, Bulgaria;  ns.nikolova@yahoo.com

REFERENCES:
1. Chang JJ, Lewin SR. Immunopathogenesis of hepatitis B virus infection. Immunol Cell Biol. 2007 Jan;85(1):16-23. Epub 2006 Nov 28. [PubMed] [CrossRef]
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005 Sep;5(9):558-567. [PubMed] [CrossRef]
3. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S35-46. [PubMed] [CrossRef]
4. Manesis EK, Hadziyannis ES, Angelopoulou OP, Hadziyannis SJ. Prediction of treatment-related HBsAg loss in HBeAG-negative chronic hepatitis B: a clue from serum HBsAg levels. Antivir Ther. 2007; 12(1):73-82. [PubMed]
5. Martin CM, Welge JA, Shire NJ, Shata MT, Sherman KE, Blackard JT. Cytokine expression during chronic versus occult hepatitis B virus infection in HIV co-infected individuals; Cytokine. 2009 Sep;47(3):194-198. Epub. 2009 Jul 21. [PubMed] [CrossRef]
6. Bekisz J, Schmeisser H, Hernandez J, Goldman ND, Zoon KC. Human interferons alpha, beta and omega. Growth Factors. 2004 Dec;22(4):243-51. [PubMed] [CrossRef]
7. Woltman AM, Op den Brouw ML, Biesta PJ, Shi CC, Janssen HL. Hepatitis B Virus Lacks Immune Activating Capacity, but Actively Inhibits Plasmacytoid Dendritic Cell Function. PLoS One. 2011 Jan 5;6(1):e15324. Epub 2011 Jan 5. [PubMed] [CrossRef]
8. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest. 2009 Jul; 119(7):1745-54]. Epub 2009 Jul 1. [PubMed] [CrossRef]
9. Askarieh G. Immunological and Genetic Markers Predicting Treatment Outcome in Hepatitis C VirusInfection; Department of Infectious Diseases Institute of Biomedicine Sahlgrenska Academy at University of Gothenburg, 2011.
10. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol. 2005 Mar;5(3):215–229. [PubMed] [CrossRef].
11. Boonstra A, Woltman AM, Janssen HL. Immunology of hepatitis B and hepatitis C virus infections. Best Pract Res Clin Gastroenterol. 2008 Dec;22(6):1049-1061. [PubMed] [CrossRef]
12. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, et al. Intrahepatic levels of CXCR3  associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology. 2008 Nov;48(5):1440-50. [Pub Med] [CrossRef].

Accepted for publication: 24 April 2013
Published online: 04 August 2013

back to Online Journal